相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2016)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis
Andrea Primiani Moy et al.
JAMA DERMATOLOGY (2015)
Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
H. Saeki et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: A randomized, dose-escalation, placebo-controlled study
Nemoto Osamu et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial
R. Bissonnette et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist
Kazumitsu Sugiura et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis
Senem Buyukkara Yilmaz et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2012)
Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab
Hideshi Torii et al.
JOURNAL OF DERMATOLOGY (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma
Hideshi Torii et al.
JOURNAL OF DERMATOLOGY (2011)
Interleukin-36-Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
Slaheddine Marrakchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis
Y. Teraki et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
European S3-Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells
Michelle A. Lowes et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
分享论文
